ArticlePsoriasis (Auckland, N.Z.)2026
Secukinumab and Adalimumab on Bone Health in Psoriasis: A Longitudinal Cohort Study.
Article in Psoriasis (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is associated with skeletal comorbidities, but longitudinal data on bone outcomes in patients receiving biologics are limited. Objective: To compare bone mineral density (BMD) and bone turnover marker trajectories among patients with psoriasis initiating secukinumab or adalimumab. Methods: In this retrospective cohort study, 364 patients with psoriasis who initiated secukinumab or adalimumab between 2021 and 2024 were screened. Of these, 50 patients had a valid baseline dual-energy X-ray absorptiometry (DXA) assessment and at least one post-baseline DXA assessment, contributing 128 DXA assessments in total. In addition, 91 patients had a valid baseline bone-turnover-marker measurement and at least one post-baseline measurement, contributing 265 biomarker observations. Longitudinal trajectories were compared using covariate-adjusted, overlap-weighted linear mixed-effects models including treatment, time, and treatment-by-time interaction terms. Results: Secukinumab was associated with more favorable lumbar spine (β = 0.039; 95% CI, 0.019-0.059; P<0.001) and femoral neck BMD trajectories (β = 0.022; 95% CI, 0.005-0.039; P=0.012). Secukinumab was also associated with increased osteocalcin and reduced CTX trajectories, whereas P1NP did not differ significantly. Limitations: Limitations include the retrospective single-center design, modest sample size, treatment imbalance, surrogate outcomes, and potential residual confounding. Conclusion: Compared with adalimumab, secukinumab was associated with more favorable longitudinal BMD trajectories and a bone turnover profile consistent with increased formation and reduced resorption in patients with psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.